Kabeer Aziz
Director/Board Member chez AN2 THERAPEUTICS, INC.
Fortune : 8 M $ au 31/03/2024
Profil
Kabeer Aziz is the founder of Adjuvant Capital LP, which was founded in 2018.
He currently holds director positions at Minervax ApS, Pulmocide Ltd., Univercells SA, Frontier Nutrition, Inc., LimmaTech Biologics AG, AN2 Therapeutics, Inc., and Quantoom Biosciences SA. He previously worked as an associate at Metalmark Capital LLC from 2013 to 2015, an analyst at Greenhill & Co., Inc., and a senior associate at Global Health Investment Fund from 2015 to 2018.
Mr. Aziz received his undergraduate degree from The Leonard N Stern School of Business in 2011.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
AN2 THERAPEUTICS, INC.
7,98% | 16/01/2024 | 2 373 500 ( 7,98% ) | 8 M $ | 31/03/2024 |
Postes actifs de Kabeer Aziz
| Sociétés | Poste | Début |
|---|---|---|
| AN2 THERAPEUTICS, INC. | Director/Board Member | 01/11/2019 |
Adjuvant Capital LP
 Adjuvant Capital LP Investment ManagersFinance Adjuvant Capital LP (Adjuvant Capital) is a private equity and venture capital firm founded in 2018 by Glenn Rockman, Kabeer Aziz and Charlie Petty. The firm is headquartered in New York. | Founder | 10/01/2018 |
Minervax ApS
 Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | Director/Board Member | - |
Pulmocide Ltd.
 Pulmocide Ltd. Pharmaceuticals: MajorHealth Technology Pulmocide Ltd. provides biopharmaceutical services. It develops inhaled medicines for viral and fungal infections of the respiratory tract. The company was founded by William Garth Rapeport, John Murray, Kazuhiro Ito, and Peter Strong on March 23, 2007 and is headquartered in London, the United Kingdom. | Director/Board Member | - |
Quantoom Biosciences SA
 Quantoom Biosciences SA Pharmaceuticals: OtherHealth Technology Quantoom Biosciences SA is a Belgian company that is focused on revolutionizing mRNA production through the development of their platform, ntensify. The private company is based in Nivelles, Belgium. This platform includes DNA amplification and RNA manufacturing, with the ntensify systems being the core of their RNA production technology. The company is made up of a team of scientists, engineers, and clinicians who are dedicated to addressing the major challenges in DNA and RNA production for vaccines and therapeutics. | Director/Board Member | - |
Frontier Nutrition, Inc.
 Frontier Nutrition, Inc. Food: Specialty/CandyConsumer Non-Durables Frontier Nutrition, Inc. develops and manufactures fortified packaged food. Its recipes are localized for traditional diets, taste, and nutrition. The company was founded by Eddie Bearnot and Tanveer Ali on August 18, 2016 and is headquartered in DE. | Director/Board Member | - |
Univercells SA
 Univercells SA BiotechnologyHealth Technology Univercells SA designs single-use cost-efficient bioprocess solutions to open the next chapter in bio manufacturing. The company was founded by Jose Castillo, Guillaume De Viron and Hugues Bultot in 2013 and is headquartered in Gosselies, Belgium. | Director/Board Member | - |
LimmaTech Biologics AG
 LimmaTech Biologics AG Miscellaneous Commercial ServicesCommercial Services LimmaTech Biologics AG is a clinical stage biopharmaceutical company based in Schlieren, Switzerland. LimmaTech Biologics is dedicated to combating the antimicrobial resistance epidemic by developing vaccines using its proprietary self-adjuvanting and multi-antigen vaccine platform, alongside additional disease-specific vaccine approaches. The Swiss company has decades of expertise and an expanding pipeline, and is focused on generating protective solutions to deliver transformative value worldwide. The company was founded in 2015 by Philippe Dro, Michael Wacker, Paul Wolfarm, Michael Kowarik, Veronica Gambillara Fonck. Franz-Werner Haas has been the CEO of the company since 2023. | Director/Board Member | 09/10/2023 |
Anciens postes connus de Kabeer Aziz
| Sociétés | Poste | Fin |
|---|---|---|
Global Health Investment Fund
 Global Health Investment Fund Investment ManagersFinance Global Health Investment Fund seeks investment opportunities in global health technologies. The fund invests in new drugs & vaccines, emerging diagnostic tools, child-friendly formulations of existing products, expanding manufacturing capacity and other applications. It provides financing in the form of mezzanine for later-stage capital requirements. | Private Equity Analyst | 31/12/2018 |
| ░░░░░░░░░ ░░░░░░░ ░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formation de Kabeer Aziz
| The Leonard N Stern School of Business | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| GREENHILL & CO., INC. | Finance |
| AN2 THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 9 |
|---|---|
Metalmark Capital LLC
 Metalmark Capital LLC Investment ManagersFinance Metalmark Capital LLC (Metalmark Capital) is a private equity firm founded by John J. Moon in 1986. The firm is headquartered in New York. | Finance |
Minervax ApS
Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | Health Technology |
Pulmocide Ltd.
Pulmocide Ltd. Pharmaceuticals: MajorHealth Technology Pulmocide Ltd. provides biopharmaceutical services. It develops inhaled medicines for viral and fungal infections of the respiratory tract. The company was founded by William Garth Rapeport, John Murray, Kazuhiro Ito, and Peter Strong on March 23, 2007 and is headquartered in London, the United Kingdom. | Health Technology |
Global Health Investment Fund
Global Health Investment Fund Investment ManagersFinance Global Health Investment Fund seeks investment opportunities in global health technologies. The fund invests in new drugs & vaccines, emerging diagnostic tools, child-friendly formulations of existing products, expanding manufacturing capacity and other applications. It provides financing in the form of mezzanine for later-stage capital requirements. | Finance |
Univercells SA
Univercells SA BiotechnologyHealth Technology Univercells SA designs single-use cost-efficient bioprocess solutions to open the next chapter in bio manufacturing. The company was founded by Jose Castillo, Guillaume De Viron and Hugues Bultot in 2013 and is headquartered in Gosselies, Belgium. | Health Technology |
Frontier Nutrition, Inc.
Frontier Nutrition, Inc. Food: Specialty/CandyConsumer Non-Durables Frontier Nutrition, Inc. develops and manufactures fortified packaged food. Its recipes are localized for traditional diets, taste, and nutrition. The company was founded by Eddie Bearnot and Tanveer Ali on August 18, 2016 and is headquartered in DE. | Consumer Non-Durables |
Adjuvant Capital LP
Adjuvant Capital LP Investment ManagersFinance Adjuvant Capital LP (Adjuvant Capital) is a private equity and venture capital firm founded in 2018 by Glenn Rockman, Kabeer Aziz and Charlie Petty. The firm is headquartered in New York. | Finance |
LimmaTech Biologics AG
LimmaTech Biologics AG Miscellaneous Commercial ServicesCommercial Services LimmaTech Biologics AG is a clinical stage biopharmaceutical company based in Schlieren, Switzerland. LimmaTech Biologics is dedicated to combating the antimicrobial resistance epidemic by developing vaccines using its proprietary self-adjuvanting and multi-antigen vaccine platform, alongside additional disease-specific vaccine approaches. The Swiss company has decades of expertise and an expanding pipeline, and is focused on generating protective solutions to deliver transformative value worldwide. The company was founded in 2015 by Philippe Dro, Michael Wacker, Paul Wolfarm, Michael Kowarik, Veronica Gambillara Fonck. Franz-Werner Haas has been the CEO of the company since 2023. | Commercial Services |
Quantoom Biosciences SA
Quantoom Biosciences SA Pharmaceuticals: OtherHealth Technology Quantoom Biosciences SA is a Belgian company that is focused on revolutionizing mRNA production through the development of their platform, ntensify. The private company is based in Nivelles, Belgium. This platform includes DNA amplification and RNA manufacturing, with the ntensify systems being the core of their RNA production technology. The company is made up of a team of scientists, engineers, and clinicians who are dedicated to addressing the major challenges in DNA and RNA production for vaccines and therapeutics. | Health Technology |
